A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer-Reference-Cited by-同舟云学术

A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer

Published:2022-03 Issue: Volume:24 Page:102-116
ISSN:2329-0501
Container-title:Molecular Therapy - Methods & Clinical Development
language:en
Short-container-title:Molecular Therapy - Methods & Clinical Development

Author:

Chaurasiya Shyambabu^ORCID,Yang Annie,Zhang Zhifang,Lu Jianming,Valencia Hannah,Kim Sang-In,Woo Yanghee,Warner Suanne G.^ORCID,Olafsen Tove,Zhao Yuqi,Wu Xiwei^ORCID,Fein Seymour^ORCID,Cheng Linda,Cheng Maria,Ede Nicholas^ORCID,Fong Yuman

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Genetics,Molecular Biology,Molecular Medicine

Reference30 articles.

1. Oncolytic virotherapy for cancer: clinical experience;Chaurasiya;Biomedicines,2021

2. Talimogene laherparepvec: first in class oncolytic virotherapy;Conry;Hum. Vaccin. Immunother.,2018

3. Oncolytic viruses: a new class of immunotherapy drugs;Kaufman;Nat. Rev. Drug Discov.,2016

4. Oncolytic viruses and immunity;Chaurasiya;Curr. Opin. Immunol.,2018

5. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma;Puzanov;J. Clin. Oncol.,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using Oncolytic Virus to Retask CD19-Chimeric Antigen Receptor T Cells for Treatment of Pancreatic Cancer: Toward a Universal Chimeric Antigen Receptor T-Cell Strategy for Solid Tumor;Journal of the American College of Surgeons;2024-03-15

2. Oncolytic Viruses and Immune Checkpoint Inhibitors: The “Hot” New Power Couple;Cancers;2023-08-19

3. Triple-Negative Breast Cancer: Basic Biology and Immuno-Oncolytic Viruses;Cancers;2023-04-21

4. Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases;Journal for ImmunoTherapy of Cancer;2023-04

5. CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study;Therapeutic Advances in Medical Oncology;2023-01